Biogen Inc (BIIB) Stock Price, Quote & News

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referenc...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 617 679 2000

Website: www.biogen.com

Address:

225 Binney Street, Cambridge, United States

Dopamineaddict May. 31 at 12:13 PM

$ANVS Another pump. Buntanetap is the "statin" of neurodegeneration. Like statins block cholesterol, it binds the IRE to inhibit translation of multiple neurotoxic proteins upstream. PROVEN (Active Phase 3 Catalysts) Alzheimer’s: Lowers pTau217 & amyloid beta; improved cognition in mild AD. Parkinson’s: Drops alpha-synuclein & inflammation (sTREM2 down 43%); halted decline. SPECULATIVE (Biomarker Extrapolations) (Note: Mechanism works, but observed in AD/PD trials—no active ALS/MS trials yet). ALS: Smashed TDP-43 (ALS core protein) by ~72% in plasma. MS: Reduces GFAP & NfL (markers tracking MS severity). If Phase 3 replicates, its safety (oral, zero ARIA/brain bleeds) makes it an existential threat to $BIIB & $LLY. Massive pipeline opportunity for a giant like $NVS to conquer the space.

1 · Reply

dogDazeSummer May. 30 at 3:14 PM

$IFRX Late Friday Oppenheimer upgrade: “We are updating our IFRX model to reflect izicopan's pivot to ANCA-associated vasculitis (AAV) as the lead indication, alongside the recently closed $150M equity raise that extends runway through 2029E, increasing our price target to $9 from $5. The PT increase is primarily driven by a shift in underlying value drivers——izicopan's HS has been deprioritized to a partnered, royalty-based opportunity, while AAV emerges as the new lead value driver representing a meaningfully larger commercial opportunity (~$3.0B combined US + EU peak sales in 2040E at 30%E (PoS). With financing risk materially reduced and a defined development roadmap in place, we believe IFRX offers asymmetric exposure to the C5aR class ahead of Capital Markets Day this summer. $AMGN $BIIB $RHHBY $PFE The 2029 runway opens M&A windows and we are now an odds on favorite w AAV given multiple Avacopan unforgivable “errors”. FDA simply can’t look the other way.

0 · Reply

Dopamineaddict May. 29 at 10:31 AM

$ANVS Big Pharma is playing a high-stakes game of chicken. The multi-billion-dollar AD landscape is built on IV monoclonals like $BIIB's Leqembi and $LLY's Kisunla, which require heavy clinic infusions and carry black-box warnings for ARIA brain bleeding. Buntanetap is an existential threat: an oral, once-daily pill that stops toxic proteins upstream, completely avoiding ARIA. The Phase 2/3 data already proves it works. Isolating mild AD patients positive for the pTau217 biomarker showed massive statistical significance. The 15mg and 30mg daily doses delivered clear cognitive improvements on the ADAS-Cog11 scale, tracking a 2.79 and 3.32 point improvement respectively, compared to a flat 0.3 for placebo. If Phase 3 hits on this pTau217 cohort, a buyout becomes a certainty. They will be forced to acquire it just to protect their market share from getting wiped out overnight. Defensive acquisition?

2 · Reply

BillionerOfKing May. 27 at 3:56 PM

$BIIB Current Stock Price: $199.24 Contracts to trade: $200.0 BIIB May 29 2026 Call Entry: $1.00 Exit: $1.73 ROI: 73% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

FannyPackin May. 27 at 3:30 PM

$BIIB missed that one spike to 225 the other week. Will get rid of half 220-225 and place stop on other half and hope for 230-240 to get rid of rest.. not saying can’t go back to 300 eventually but needs lot of time to get through volume 225-240

2 · Reply

CapitalMonk May. 25 at 8:44 PM

$BIIB Price: $193.76 (+2.26%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.45% RSI: 57.6 | Momentum: Moderate Volume: -26.5% vs avg Volatility: 2.47% Support: $179.15 | Resistance: $205.97 Sourch: http://marketbaubles.com/

0 · Reply

ksoption May. 24 at 3:18 PM

$GNRC $ON $BIIB

0 · Reply

Cad_Bane May. 22 at 6:12 PM

$BIIB failure after failure after failure. They laid off all foot troops but jept the same arrogant leadership - heads shoikd roll but rhey won’t because those DEI leaders will sue.

1 · Reply

MQuick May. 22 at 1:21 PM

$GANX time to invest in us $BIIB the first disease modiying drug for PD!

0 · Reply

notreload_ai May. 22 at 12:30 PM

$DNLI, $BIIB - Experimental Parkinson’s drug BIIB122 failed to slow disease in trials despite strong biological effects; development stopped. https://notreload.xyz/xy/biogen-denali-halt-biib122-after-parkinson-phase-2-failure/

0 · Reply

Market Cap	28.94B
Revenue (ttm)	9.89B
Net Income (ttm)	1.29B
EPS (ttm)	N/A
PE Ratio	12.40
Forward PE	13.85
Profit Margin	13.07%
Debt to Equity Ratio	0.34

Volume	841,500
Avg Vol	1,230,700
Day's Range	N/A - N/A
Shares Out	147.64M
Stochastic %K	73%
Beta	0.19
Analysts	Strong Sell
Price Target	$219.14